carmustine has been researched along with Ependymoma in 21 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Ependymoma: Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 5.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| "We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours." | 3.68 | Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. ( Gattamaneini, HR; Hasleton, PS; Kalra, SJ; Lynch, P; O'Driscoll, BR; Poulter, LW; Webster, A; Woodcock, AA, 1991) |
| "Thirteen of 19 (68%) evaluable primary brain tumors and 9 of 16 (56%) evaluable brain metastases responded." | 2.65 | Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary ( Addison, D; Benoit, B; Dennery, J; Grahovac, Z; Hugenholtz, H; Maroun, JA; Peterson, E; Richard, MT; Russell, N; Stewart, DJ, 1984) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 1.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| " Sorted populations of cells from 5 tumors had dose-response curves that were similar, although differences in cell kill of up to a half-log were commonly found between cells from different DNA peaks treated with the same BCNU dose." | 1.27 | Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content. ( Dougherty, DV; Hoshino, T; Kobayashi, S; Rosenblum, ML, 1984) |
| "She developed progressive, pulmonary fibrosis as a consequence of chemotherapy, which lead to her death." | 1.27 | Chemotherapy-induced fatal pulmonary fibrosis. ( Révész, T; Somló, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (71.43) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crider, AM | 1 |
| Kolczynski, TM | 1 |
| Yates, KM | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Delattre, JY | 1 |
| Sardi, I | 1 |
| Sanzo, M | 1 |
| Giordano, F | 1 |
| Sandri, A | 1 |
| Mussa, F | 1 |
| Donati, PA | 1 |
| Genitori, L | 1 |
| Kobayashi, S | 1 |
| Hoshino, T | 1 |
| Dougherty, DV | 1 |
| Rosenblum, ML | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Benoit, B | 1 |
| Addison, D | 1 |
| Richard, MT | 1 |
| Dennery, J | 1 |
| Hugenholtz, H | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Maroun, JA | 1 |
| Somló, P | 2 |
| Révész, T | 2 |
| Röttinger, EM | 1 |
| Geyer, JR | 1 |
| Zeltzer, PM | 1 |
| Boyett, JM | 1 |
| Rorke, LB | 1 |
| Stanley, P | 1 |
| Albright, AL | 1 |
| Wisoff, JH | 1 |
| Milstein, JM | 1 |
| Allen, JC | 1 |
| Finlay, JL | 1 |
| Coggins, CA | 1 |
| Elion, GB | 1 |
| Houghton, PJ | 1 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Colvin, OM | 1 |
| Bigner, DD | 1 |
| Friedman, HS | 1 |
| Levin, VA | 1 |
| Crafts, DC | 2 |
| Wilson, CB | 3 |
| Schultz, MJ | 1 |
| Boldrey, EB | 3 |
| Enot, KJ | 3 |
| Pischer, TL | 1 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Paoletti, P | 2 |
| Baldini, M | 1 |
| Knerich, R | 1 |
| Princi, L | 1 |
| Fumagalli, R | 1 |
| Weiss, JF | 1 |
| Pezzotta, S | 1 |
| Wara, WM | 1 |
| Sheline, GE | 1 |
| Shapiro, WR | 2 |
| Calogero, J | 1 |
| Rosenberg, A | 1 |
| Hasleton, PS | 1 |
| O'Driscoll, BR | 1 |
| Lynch, P | 1 |
| Webster, A | 1 |
| Kalra, SJ | 1 |
| Gattamaneini, HR | 1 |
| Woodcock, AA | 1 |
| Poulter, LW | 1 |
| Salcman, M | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Jacobi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Ependymoma
| Article | Year |
|---|---|
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
3 trials available for carmustine and Ependymoma
| Article | Year |
|---|---|
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
16 other studies available for carmustine and Ependymoma
| Article | Year |
|---|---|
Synthesis and anticancer activity of nitrosourea derivatives of phensuximide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Ependymoma; Leukemia L1210; Mice; Neoplasms, Experi | 1980 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Brain; Brain Neoplasms; Carm | 2008 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Chemotherapy-induced fatal pulmonary fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Epend | 1984 |
[Fatal pulmonary fibrosis induced by cytotoxic therapy].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Ependymoma; Female; Hum | 1984 |
[Survival of children with primitive neuroectodermal tumors and malignant ependymomas of the central nervous system after treatment with 8 cytostatic agents in one day. A report of the Children's Cancer Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabine; Ependymoma; | 1995 |
Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Cyclophospha | 1994 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
Topics: Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Ependymoma; Humans; Lung; Medulloblastoma; Microsc | 1991 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |